Thomas Ulmer
Director/Board Member at Aravax Pty Ltd.
Thomas Ulmer active positions
| Companies | Position | Start | End |
|---|---|---|---|
Aravax Pty Ltd.
 Aravax Pty Ltd. BiotechnologyHealth Technology Aravax Pty Ltd. develops treatments for peanut allergies. The company was founded in May 2015 and is headquartered in Melbourne, Australia. | Director/Board Member | 31/10/2020 | - |
Career history of Thomas Ulmer
Former positions of Thomas Ulmer
| Companies | Position | Start | End |
|---|---|---|---|
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Chief Executive Officer | 31/03/2018 | 11/02/2020 |
| MERCK KGAA | Corporate Officer/Principal | 31/03/2012 | 30/06/2016 |
| IMMATICS N.V. | Director of Finance/CFO | 30/06/2020 | - |
Training of Thomas Ulmer
| University of Giessen | Masters Business Admin |
Statistics
International
| Germany | 5 |
| Australia | 2 |
Operational
| Director of Finance/CFO | 1 |
| Masters Business Admin | 1 |
| Chief Executive Officer | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| MERCK KGAA | Health Technology |
| IMMATICS N.V. | Health Technology |
| Private companies | 2 |
|---|---|
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
Aravax Pty Ltd.
Aravax Pty Ltd. BiotechnologyHealth Technology Aravax Pty Ltd. develops treatments for peanut allergies. The company was founded in May 2015 and is headquartered in Melbourne, Australia. | Health Technology |
- Stock Market
- Insiders
- Thomas Ulmer
- Experience
